V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Arcus Biosciences Executive Compensation (FY25)

RCUS · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): June 12, 2026
235 figures on this page: 229 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
Terry Rosen was paid $9,656,813 in total compensation as Chief Executive Officer and Director for fiscal 2025, and Rosen's total moved 32.7% higher from the $7,279,504 reported for fiscal 2024. For fiscal 2025, the say-on-pay proposal drew 91.0% support at the meeting held June 11, 2026. The disclosed peer group includes Alector, Inc., Allogene Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Arvinas, Inc. and BridgeBio Pharma, Inc., among others. For fiscal 2025, the company reported 5 named executive officers.
Chief executive, fiscal 2025
◇
Terry Rosen
Latest say-on-pay support
=
June 11, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Terry Rosen: $7,279,504 → $9,656,813 (32.7% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Arcus Biosciences' chief executive and what were they paid?
Terry Rosen was paid $9,656,813 in total compensation as Chief Executive Officer and Director for fiscal 2025. Rosen's total moved 32.7% higher from the $7,279,504 reported for fiscal 2024.
What was Arcus Biosciences' say-on-pay result?
For fiscal 2025, the say-on-pay proposal drew 91.0% support at the meeting held June 11, 2026.
Which companies are in Arcus Biosciences' peer group?
The disclosed peer group includes Alector, Inc., Allogene Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Arvinas, Inc. and BridgeBio Pharma, Inc., among others.
What is Arcus Biosciences' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 35.9:1, against median employee compensation of $269,269.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Terry Rosen
Chief Executive Officer and Director
◇—◇◇◇—◇◇
Juan Carlos Jaen
President
◇—◇◇◇—◇◇
Jennifer Jarrett
Chief Operating Officer
◇—◇◇◇—◇◇
Robert Goeltz
Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Terry Rosen
Chief Executive Officer and Director
◇—◇◇◇—◇◇
Juan Carlos Jaen
President
◇—◇◇◇—◇◇
Jennifer Jarrett
Chief Operating Officer
◇—◇◇◇—◇◇
Robert Goeltz
Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Terry Rosen
Chief Executive Officer and Director
◇—◇◇◇—◇◇
Richard Markus
Chief Medical Officer
◇◇◇◇◇—◇◇
Juan Carlos Jaen
President
◇—◇◇◇—◇◇
Jennifer Jarrett
Chief Operating Officer
◇—◇◇◇—◇◇
Robert Goeltz
Chief Financial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Jennifer JarrettRSU◇——◇——◇
Jennifer JarrettOPTION◇——◇—◇◇
Juan CarlosOPTION◇——◇—◇◇
Juan CarlosRSU◇——◇——◇
Richard MarkusRSU◇——◇——◇
Robert C. Goeltz IIOPTION◇——◇—◇◇
Robert C. Goeltz IIRSU◇——◇——◇
Terry RosenRSU◇——◇——◇
Terry RosenOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Juan JaenRSU◇◇——
Option◇—◇1/22/2034
RSU◇◇——
Option◇—◇1/22/2035
Option◇—◇3/7/2032
Option◇—◇1/22/2033
RSU◇◇——
Jennifer JarrettRSU◇◇——
Option◇—◇2/9/2035
RSU◇◇——
Option◇—◇1/22/2035
Option◇—◇3/7/2032
Option◇—◇1/22/2033
RSU◇◇——
RSU◇◇——
Option◇—◇1/22/2034
Terry RosenOption◇—◇1/22/2034
RSU◇◇——
Option◇—◇3/7/2032
Option◇—◇1/22/2035
RSU◇◇——
RSU◇◇——
Option◇—◇1/22/2033
Robert GoeltzOption◇—◇3/7/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/22/2033
Option◇—◇1/22/2035
Option◇—◇1/22/2034
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Lacey, M.D
◇◇◇——◇◇
Antoni Ribas, M.D., Ph.D
◇◇◇——◇◇
Yasunori Kaneko, M.D
Lead independent director
◇◇◇———◇
Andrew Perlman, M.D., Ph.D
◇◇◇———◇
Kathryn Falberg
◇◇◇———◇
Nicole Lambert
◇◇◇———◇
Patrick Machado, J.D
◇◇◇———◇
Dietmar Berger, M.D., Ph.D, Johanna Mercier, Linda Higgins, Ph.D and Terry Rosen, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Alector, Inc. ALEC
  • Allogene Therapeutics, Inc. ALLO
  • Arrowhead Pharmaceuticals, Inc. ARWR
  • Arvinas, Inc. ARVN
  • BridgeBio Pharma, Inc. BBIO
  • Day One Biopharmaceuticals, Inc. DAWN
  • Denali Therapeutics Inc. DNLI
  • Editas Medicine, Inc. EDIT
  • ImmunityBio, Inc. IBRX
  • Intellia Therapeutics Inc. NTLA
  • Iovance Biotherapeutics, Inc. IOVA
  • Kura Oncology, Inc. KURA
  • Prothena Corporation Plc PRTA
  • REGENXBIO Inc. RGNX
  • SpringWorks Therapeutics, Inc. SWTX
  • Syndax Pharmaceuticals Inc. SNDX
  • Xencor Inc. XNCR

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 11, 2026=◇◇◇
2024June 10, 2025=◇◇◇
2023June 6, 2024=◇◇◇
2022June 15, 2023=◇◇◇
2021June 14, 2022=◇◇◇
2020June 3, 2021=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Arcus Biosciences files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Arcus Biosciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Arcus Biosciences sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Arcus Biosciences' disclosed peer group is defensible, who names Arcus Biosciences back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
235 figures on this page: 229 cited to the filing that reported them, 6 calculated from figures it prints.
229 cited to the filing
6 calculated from the filing

Documents cited

  1. 0001724521-26-000037
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001724521-26-000025
    2025 Grants of Plan-Based Awards · CEO Pay Ratio · COMPENSATION OF DIRECTORS · Director Compensation for Fiscal 2025 · and 3 more sections
  3. 0001724521-25-000078
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001724521-25-000052
    Summary Compensation Table
  5. 0001724521-24-000101
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001724521-24-000079
    Summary Compensation Table
  7. 0000950170-23-028621
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0000950170-22-011747
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001564590-21-031965
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Arcus Biosciences executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/RCUS (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Arcus Biosciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Arcus Biosciences discloses

The companies named in RCUS's own disclosed peer group.

Allogene Therapeutics, Inc.Arrowhead Pharmaceuticals, Inc.Arvinas, Inc.BridgeBio Pharma, Inc.Denali Therapeutics Inc.Kura Oncology, Inc.REGENXBIO Inc.Syndax Pharmaceuticals Inc.Xencor Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy